17.70SEK-2.21%Mkt Cap: 476.93M SEKP/E: —Last update: 2026-05-13
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on C…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)20.51
PEG—
P/B4.98
P/S55.55
EV/EBITDA-29.39
EV/Revenue50.26
EPS (TTM)-0.59
EPS (Forward)0.89
Cash Flow & Leverage
FCF Yield-3.15%
FCF Margin-174.96%
Operating CF-17.69M SEK
CapEx (TTM)983.00K SEK
Net Debt/EBITDA1.14
Net Debt-16.72M SEK
Technical
SMA 5016.15 (+9.6%)
SMA 20016.60 (+6.6%)
Beta0.30
S&P 52W Chg24.23%
Avg Vol (30d)16.54K
Avg Vol (10d)24.64K
Technical Indicators
RSI (14)62.8
MACD0.3616
MACD Signal0.1154
MACD Hist.+0.2462
BB Upper18.04 SEK
BB Middle16.28 SEK
BB Lower14.52 SEK
BB Width21.62%
ATR (14)0.8939 SEK
Vol Ratio (20d)0.19x
52W Range
9.48046% of range27.20
52W High27.20 SEK
52W Low9.480 SEK
Profitability
Gross Margin81.37%
EBITDA Margin-170.99%
Profit Margin-192.31%
Oper. Margin-236.16%
ROE-15.69%
ROA-14.93%
Revenue Growth-12.20%
Earnings Growth—
Balance Sheet
Debt/Equity4.09
Current Ratio4.98
Quick Ratio4.74
Book Value/Sh3.661 SEK
Cash/Share0.8030 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.26.13M
Float11.08M
Insiders61.15%
Institutions4.58%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)29.00 SEK
Target Range29.00 SEK – 29.00 SEK
# Analysts1
Company
Market Cap476.93M SEK
Enterprise Value431.51M SEK
Revenue (TTM)8.59M SEK
Gross Profit6.23M SEK
Net Income (TTM)-14.71M SEK
Revenue/Share0.3470 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees12
Last Price17.70 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—